Seres Therapeutics (NASDAQ:MCRB) Stock Rating Upgraded by Zacks Research

Seres Therapeutics (NASDAQ:MCRB) was upgraded by equities researchers at Zacks Research to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

MCRB has been the subject of several other research reports. Wall Street Zen raised shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. HC Wainwright initiated coverage on shares of Seres Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $12.00 target price for the company. Canaccord Genuity Group reiterated a “buy” rating and set a $22.00 target price on shares of Seres Therapeutics in a report on Friday, March 13th. Finally, Weiss Ratings downgraded Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $17.00.

Seres Therapeutics Stock Down 3.2%

MCRB stock opened at $6.83 on Tuesday. Seres Therapeutics has a twelve month low of $5.31 and a twelve month high of $29.98. The business’s fifty day moving average is $7.43 and its 200-day moving average is $10.59. The company has a market cap of $66.07 million, a P/E ratio of -1.32 and a beta of 0.13.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The firm had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.36 million. Research analysts anticipate that Seres Therapeutics will post -5.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Seres Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE grew its stake in shares of Seres Therapeutics by 2,772.6% in the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 5,157 shares in the last quarter. Barclays PLC boosted its stake in shares of Seres Therapeutics by 427.8% in the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 6,024 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in Seres Therapeutics in the 4th quarter worth about $190,000. Goldman Sachs Group Inc. bought a new position in Seres Therapeutics in the fourth quarter valued at about $213,000. Finally, Invesco Ltd. boosted its stake in shares of Seres Therapeutics by 37.5% during the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 3,918 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.